ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Long-Acting Corticosteroid (Joint Injection) Pregnancy: Use with caution — minimal systemic absorption; specialist advice required

Betamethasone Dipropionate

Brand names: Celestone Soluspan, Diprospan

Adult dose

Dose: Large joints (knee, shoulder): 1–2 mL (3–6 mg betamethasone dipropionate); Small joints: 0.25–0.5 mL
Route: Intra-articular or periarticular or bursal
Frequency: Every 3–4 months; maximum 3–4 injections per joint per year
Max: Maximum 3–4 injections per joint per year
Compound formulation: soluble betamethasone phosphate (rapid onset) plus poorly soluble dipropionate (sustained 3–4 weeks); aspirate joint before injecting if effusion present; avoid repeat injections less than 4 weeks apart

Paediatric dose

Route: Intra-articular
Frequency: Variable
Max: 0.02–0.125 mg/kg
Specialist use only in paediatric OA or JIA

Dose adjustments

Renal

No dose adjustment required for intra-articular use

Hepatic

No adjustment required

Clinical pearls

  • Dual-release compound: betamethasone dipropionate provides sustained release (3–4 weeks) plus betamethasone sodium phosphate provides rapid soluble component (onset within hours) — biphasic profile differentiates Diprospan from triamcinolone which is single-component slow release
  • OA knee injections: NICE CG177 (OA) recommends intra-articular corticosteroids for moderate-to-severe pain when pharmacological therapy insufficient — short-term pain relief demonstrated (4–6 weeks); no evidence of long-term disease modification
  • Diabetic patients: single knee injection can raise blood glucose 5–10 mmol/L over 24–48 hours — warn patients and advise blood glucose monitoring; not a contraindication but requires monitoring
  • Post-injection flare: up to 10% of patients develop increased pain and swelling within 12–24 hours — caused by microcrystalline corticosteroid particles triggering synovitis; resolves spontaneously within 48 hours; reassure and avoid re-injection
  • Joint degeneration: repeated injections (>3–4/year) associated with accelerated cartilage loss in some studies — balance symptom control against structural harm; particularly relevant if joint replacement is planned

Contraindications

  • Joint infection (septic arthritis)
  • Bacteraemia
  • Prosthetic joint (relative — specialist decision)
  • Haemarthrosis without known cause
  • Uncontrolled diabetes (relative)
  • Coagulopathy (relative)

Side effects

  • Post-injection flare (24–48 hours, self-limiting)
  • Skin depigmentation or fat atrophy if superficial
  • Transient hyperglycaemia in diabetics
  • HPA suppression (rare with single injection)
  • Cartilage damage with repeated injections

Interactions

  • Anticoagulants — increased haematoma risk at injection site
  • Hypoglycaemics — monitor glucose in diabetics

Monitoring

  • Blood glucose in diabetics day 1–3
  • Pain response at 2–6 weeks
  • Signs of joint infection
  • Skin changes at injection site

Reference: BNFc; BNF 90; NICE CG177 (OA 2022); SPC Diprospan; Cochrane Review (IA steroids for OA knee). Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways